A MULTIPLE-DOSE STUDY OF BLOCKADE OF OPIOID SUBJECTIVE EFFECTS BY SUBCUTANEOUS INJECTIONS OF DEPOT BUPRENORPHINE IN SUBJECTS WITH OPIOID USE DISORDER

H. Jiao1, M.K. Greenwald2, B. D. Vince3, P. J. Fudala1, C. Heidbreder1, A. F. Nasser1;
1Indivior PLC, Richmond, VA, 2Wayne State University, Detroit, MI, 3Vince & Associates Clinical Research, Inc., Overland Park, KS

BACKGROUND

RBP-6000 is a 28-day SC injection of depot buprenorphine (Bup). We hypothesized (Nasser et al., 2014, Clin Pharmacokinet) that brain μ-opioid receptor occupancy (μORO) ≥ 70% and Bup plasma levels ≥ 2 ng/mL are needed to provide full blockade of opioid agonist effects. This Phase 2 study was designed to assess hydromorphone (HM) subjective and reinforcing effects in non-treatment-seeking individuals presenting with moderate or severe opioid use disorder according to DSM-V.

METHODS

Thirty-nine subjects with opioid use disorder first completed 3 HM challenges (0, 6, 18 mg intramuscular (IM)) on 3 consecutive days in randomized order, then 3 HM challenges at the end of 14-day SUBOXONE film stabilization. This was followed by two RBP-6000 300-mg SC doses separated by 28 days. For 12 weeks after the first RBP-6000 dose, on days 5-7 of each week, subjects received 3 HM challenges in randomized order (6 sequences). A Drug Liking visual analog scale (VAS) score was the primary endpoint, and HM reinforcing efficacy (IC50 breakpoint values) and Any Effects, Bad Effects, High, Good Effects, and Sedation scores were secondary endpoints. Statistical comparison using mixed effects model was used for each week. Change from HM 6 mg with 95% CI was reported, with a VAS difference cut-off of ±11 required to declare full blockade. A blood sample for PK analysis was collected the morning of each HM administration day. Our published Emax model was used to calculate μORO.

RESULTS

HM 6 mg with 95% CI was reported, with a VAS difference cut-off of ±11 required to declare full blockade. A blood sample for PK analysis was collected the morning of each HM administration day. Our published Emax model was used to calculate μORO. HM scores were collected at 30 min before and 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 min after receiving the daily HM challenge. HM reinforcing efficacy was measured at least 5 hours after the daily HM challenge. Subjects completed a 12 trial choice session during which they could work (on a progressive ratio schedule) for units of the total amount of HM dosed earlier that day or for $2 units of money. The purpose of the choice task was to evaluate the reinforcing efficacy of the daily randomized HM challenge dose relative to money.

STUDY DESIGN

![Study Design Image]

CONCLUSIONS

- At baseline (week -1), mean Bup plasma concentrations were 1.8-2 ng/mL and μOROs were 65-68%. The mean Drug Liking VAS scores were 2.9-7 (≤1, non-inferiority bound) and the mean breakpoint values were 0.9-1.9 following the 18 mg HM challenge.
- After the 2nd SC injection, mean Bup plasma concentrations were 2.6-3.7 mg/mL and μOROs were all >70%. The mean HM Drug Liking VAS scores were 0.1-4.2 and the mean breakpoint values were 0.1-1.6 with both 95% CIs including 0 after 18 mg HM challenge, confirming our hypothesis (Nasser et al., 2014, Clin Pharmacokinet) was correct.
- The mean VAS scores and breakpoints increased at the end of the 1st SC injection (weeks 4) and at the end of the 2nd SC injection (week 9), which were related to the slight decrease in Bup concentrations, confirming our 28-day dosing interval is appropriate.
- Linear model with y = 0.4079x + 2.179 (R²=0.6459) described the relationship between reinforcing efficacy VAS scores and Bup plasma concentration.
- • Findings from this study confirm the hypothesis that μORO ≥ 70% and Bup plasma levels ≥ 2 ng/mL are needed to provide full blockade of opioid agonist effects.
- • The first dose of RBP-6000 (300 mg) (within the first week) was non-inferior to sublingual buprenorphine/naloxone in blocking the subjective and reinforcing effects of HM in subjects with moderate or severe opioid use disorder.
- • RBP-6000 (300 mg) effectively blocked HM’s subjective effects and reinforcing efficacy suggesting that treatment with RBP-6000 may significantly reduce illicit opioid use. It is hoped that RBP-6000 will be useful in patients with moderate or severe opioid use disorder, and may improve patient adherence (monthly dosing) and reduce diversion, abuse and unintended exposure to Bup. RBP-6000 is currently being assessed for efficacy and safety in a phase 3 clinical trial.